Literature DB >> 27225760

Loss of Homeostasis in the Direct Pathway in a Mouse Model of Asymptomatic Parkinson's Disease.

Mariela V Escande1, Irene R E Taravini2, Camila L Zold3, Juan E Belforte3, M Gustavo Murer3.   

Abstract

UNLABELLED: The characteristic slowness of movement in Parkinson's disease relates to an imbalance in the activity of striatal medium spiny neurons (MSNs) of the direct (dMSNs) and indirect (iMSNs) pathways. However, it is still unclear whether this imbalance emerges during the asymptomatic phase of the disease or if it correlates with symptom severity. Here, we have used in vivo juxtacellular recordings and transgenic mice showing MSN-type-specific expression of fluorescent proteins to examine striatal imbalance after lesioning dopaminergic neurons of the substantia nigra. Multivariate clustering analysis of behavioral data discriminated 2 groups of dopamine-lesioned mice: asymptomatic (42 ± 7% dopaminergic neuron loss) and symptomatic (85 ± 5% cell loss). Contrary to the view that both pathways have similar gain in control conditions, dMSNs respond more intensely than iMSNs to cortical inputs in control animals. Importantly, asymptomatic mice show significant functional disconnection of dMSNs from motor cortex without changes in iMSN connectivity. Moreover, not only the gain but also the timing of the pathways is altered in symptomatic parkinsonism, where iMSNs fire significantly more and earlier than dMSNs. Therefore, cortical drive to dMSNs decreases after partial nigrostriatal lesions producing no behavioral impairment, but additional alterations in the gain and timing of iMSNs characterize symptomatic rodent parkinsonism. SIGNIFICANCE STATEMENT: Prevailing models of Parkinson's disease state that motor symptoms arise from an imbalance in the activity of medium spiny neurons (MSNs) from the direct (dMSNs) and indirect (iMSNs) pathways. Therefore, it is hypothesized that symptom severity and the magnitude of this imbalanced activity are correlated. Using a mouse model of Parkinson's disease, we found that behaviorally undetectable nigrostriatal lesions induced a significant disconnection of dMSNs from the motor cortex. In contrast, iMSNs show an increased connectivity with the motor cortex, but only after a severe dopaminergic lesion associated with an evident parkinsonian syndrome. Overall, our data suggest that the lack of symptoms after a partial dopaminergic lesion is not due to compensatory mechanisms maintaining the activity of both striatal pathways balanced.
Copyright © 2016 the authors 0270-6474/16/365686-13$15.00/0.

Entities:  

Keywords:  6-OHDA; functional connectivity; in vivo electrophysiology; medium spiny neurons; striatum

Mesh:

Year:  2016        PMID: 27225760      PMCID: PMC6601837          DOI: 10.1523/JNEUROSCI.0492-15.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  76 in total

1.  Relationship between EEG potentials and intracellular activity of striatal and cortico-striatal neurons: an in vivo study under different anesthetics.

Authors:  S Mahon; J M Deniau; S Charpier
Journal:  Cereb Cortex       Date:  2001-04       Impact factor: 5.357

2.  Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys.

Authors:  E Bezard; P Ravenscroft; C E Gross; A R Crossman; J M Brotchie
Journal:  Neurobiol Dis       Date:  2001-04       Impact factor: 5.996

Review 3.  Role of the basal ganglia in the control of purposive saccadic eye movements.

Authors:  O Hikosaka; Y Takikawa; R Kawagoe
Journal:  Physiol Rev       Date:  2000-07       Impact factor: 37.312

4.  Network synchrony in the nucleus accumbens in vivo.

Authors:  Y Goto; P O'Donnell
Journal:  J Neurosci       Date:  2001-06-15       Impact factor: 6.167

5.  Inhibitory control of neostriatal projection neurons by GABAergic interneurons.

Authors:  T Koós; J M Tepper
Journal:  Nat Neurosci       Date:  1999-05       Impact factor: 24.884

Review 6.  When inhibition goes incognito: feedback interaction between spiny projection neurons in striatal function.

Authors:  Dietmar Plenz
Journal:  Trends Neurosci       Date:  2003-08       Impact factor: 13.837

7.  Disruption of the two-state membrane potential of striatal neurones during cortical desynchronisation in anaesthetised rats.

Authors:  Fernando Kasanetz; Luis A Riquelme; M Gustavo Murer
Journal:  J Physiol       Date:  2002-09-01       Impact factor: 5.182

8.  Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.

Authors:  V Kaasinen; H M Ruottinen; K Någren; P Lehikoinen; V Oikonen; J O Rinne
Journal:  J Nucl Med       Date:  2000-01       Impact factor: 10.057

Review 9.  Presymptomatic compensation in Parkinson's disease is not dopamine-mediated.

Authors:  Erwan Bezard; Christian E Gross; Jonathan M Brotchie
Journal:  Trends Neurosci       Date:  2003-04       Impact factor: 13.837

10.  Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Authors:  E Bezard; S Dovero; C Prunier; P Ravenscroft; S Chalon; D Guilloteau; A R Crossman; B Bioulac; J M Brotchie; C E Gross
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

View more
  20 in total

Review 1.  Dopaminergic modulation of striatal function and Parkinson's disease.

Authors:  Shenyu Zhai; Weixing Shen; Steven M Graves; D James Surmeier
Journal:  J Neural Transm (Vienna)       Date:  2019-04-01       Impact factor: 3.575

Review 2.  Striatal synapses, circuits, and Parkinson's disease.

Authors:  Shenyu Zhai; Asami Tanimura; Steven M Graves; Weixing Shen; D James Surmeier
Journal:  Curr Opin Neurobiol       Date:  2017-08-24       Impact factor: 6.627

3.  Inflammation alters AMPA-stimulated calcium responses in dorsal striatal D2 but not D1 spiny projection neurons.

Authors:  Carissa D Winland; Nora Welsh; Alberto Sepulveda-Rodriguez; Stefano Vicini; Kathleen A Maguire-Zeiss
Journal:  Eur J Neurosci       Date:  2017-10-10       Impact factor: 3.386

4.  Indirect Medium Spiny Neurons in the Dorsomedial Striatum Regulate Ethanol-Containing Conditioned Reward Seeking.

Authors:  Sa-Ik Hong; Seungwoo Kang; Jiang-Fan Chen; Doo-Sup Choi
Journal:  J Neurosci       Date:  2019-07-17       Impact factor: 6.167

5.  Differential Synaptic Remodeling by Dopamine in Direct and Indirect Striatal Projection Neurons in Pitx3-/- Mice, a Genetic Model of Parkinson's Disease.

Authors:  Luz M Suarez; Samuel Alberquilla; Jose R García-Montes; Rosario Moratalla
Journal:  J Neurosci       Date:  2018-02-26       Impact factor: 6.167

6.  Dysregulation of external globus pallidus-subthalamic nucleus network dynamics in parkinsonian mice during cortical slow-wave activity and activation.

Authors:  Ryan F Kovaleski; Joshua W Callahan; Marine Chazalon; David L Wokosin; Jérôme Baufreton; Mark D Bevan
Journal:  J Physiol       Date:  2020-04-23       Impact factor: 5.182

Review 7.  Aberrant features of in vivo striatal dynamics in Parkinson's disease.

Authors:  Kwang Lee; Sotiris C Masmanidis
Journal:  J Neurosci Res       Date:  2019-09-09       Impact factor: 4.164

Review 8.  Striatal synaptic adaptations in Parkinson's disease.

Authors:  Weixing Shen; Shenyu Zhai; D James Surmeier
Journal:  Neurobiol Dis       Date:  2022-03-08       Impact factor: 7.046

9.  A Population of Indirect Pathway Striatal Projection Neurons Is Selectively Entrained to Parkinsonian Beta Oscillations.

Authors:  Andrew Sharott; Federica Vinciati; Kouichi C Nakamura; Peter J Magill
Journal:  J Neurosci       Date:  2017-08-28       Impact factor: 6.167

10.  Striatal Neurons Expressing D1 and D2 Receptors are Morphologically Distinct and Differently Affected by Dopamine Denervation in Mice.

Authors:  D Gagnon; S Petryszyn; M G Sanchez; C Bories; J M Beaulieu; Y De Koninck; A Parent; M Parent
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.